HPLC-UV Atmospheric Pressure Ionization Mass Spectrometry Determination of the Dopamine D2 Agonist N-0923 and Its Major Metabolites After Oxidative Metabolism by Rat-, Monkey-, and Human Liver Microsomes

References

• Horn A S, Tepper P G, van der Weide J, Watanabe M, Grigoriades D, Seemen P. Synthesis and radioreceptor binding activity of N-0437, a new, extremely potent and selective D2 dopamine receptor agonist. Pharm Weekbl [Sci] 1985; 7: 208–11
   PubMedGoogle Scholar
• Van der Weide J, De Vries J B, Tepper P G, Krause D N, Dubocovich M L, Horn A S. N-0437:a selective D-2 dopamine receptor agonist in in vitro and in vivo models. Eur J Pharmacol 1988; 147: 249–58
   PubMed Web of Science ®Google Scholar
• Timmerman W, Rusk I N, Tepper P G, Horn A S, Cooper S J. The effects of the enantiomers of the dopamine agonist N-0437 on food consumption and yawning behavior in rats. Eur J Pharmacol 1989; 174: 107–14
   PubMed Web of Science ®Google Scholar
• Lbschmann P A, Chong P N, Nomoto M, Tepper P G, Horn A S, Jenner P, Marsden C D. Stereoselective reversal of MPTP-induced parkinsonism in the marmoset after dermal application of N-0437. Eur J Pharmacol 1989; 166: 373–80
   PubMedGoogle Scholar
• Den Daas I, Tepper P G, Horn A S. Improvement of oral bioavailability of the selective dopamine agonist N-0437 in rats: the in-vitro and in-vivo activity of eight ester prodrugs. Naunyn Schmiedebergs Arch Pharmacol 1990; 341: 186–91
   PubMed Web of Science ®Google Scholar
• Gerding T K, Drenth B FH, Roosenstein H J, De Zeeuw R A, Tepper P G, Horn A S. The metabolic fate of the dopamine agonist 2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin in rats after intravenous and oral administration. I. Disposition and metabolic profiling. Xenobiotica 1990; 20: 515–24
   PubMed Web of Science ®Google Scholar
• Gerding T K, Drenth B FH, De Zeeuw R A, Tepper P G, Horn A S. The metabolic fate of the dopamine agonist 2-(N-propyl-N-2 thienylethylamino)-5-hydroxytetralin (N-0437) in rats after intravenous and oral administration. II. Isolation and identification of metabolites. Xenobiotica 1990; 20: 525–36
   PubMed Web of Science ®Google Scholar
• Gerding T K, Drenth B FH, De Zeeuw R A, Tepper P G, Horn A S. Metabolism and disposition of the dopamine agonist 2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin (N-0437) in conscious monkeys after subsequent intravenous, oral and ocular administration. Drug Metab Dispos 1990; 18: 923–8
   PubMed Web of Science ®Google Scholar
• Swart P J, De Zeeuw R A. Pharmacokinetics of the dopamine D2 agonist N-0923 in freely moving rats. J Pharm Sci 1993; 82: 200–3
   PubMed Web of Science ®Google Scholar
• Swart P J, De Zeeuw R A. Extensive gastrointestinal metabolic conversion limits the oral bioavailability of the dopamine D2 agonist N-0923 in freely moving rats. Die Pharmazie 1992; 47: 613–15
   PubMed Web of Science ®Google Scholar
• Ten Hoeve W, Wijnberg H. The design of resolving agents. Chiral cyclic phosphoric acids. J Org Chem 1985; 50: 4508–14
   Web of Science ®Google Scholar
• Witte D T, Franke J P, Swart P J, De Zeeuw R A. Determination of the enantiomeric purity of (-)5-hydroxy-2-(N-propyl-N-2-thienylethylamino) tetralin (N-0923) by chiral stationary phase HPLC. Chirality 1992; 4: 62–4
   Google Scholar
• Hacksell U, Svensson U, Nilsson J LG, et al. N-alkylated 2-aminotetralins: central dopamine-receptor stimulating activity. J Med Chem 1986; 22: 1469–75
   Google Scholar
• Lowry O H, Rosebrough N J, Farr A L, Randell R J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265–75
   PubMed Web of Science ®Google Scholar
• Bruins A P, Covey T R, Henion J D. Ion spray interface for combined liquid chromatographic/atmospheric pressure ionization mass spectrometry. Anal Chem 1987; 59: 2642–6
   Web of Science ®Google Scholar
• Ensing K, Bloemhof D A, In't Hout W G, Van der Lende J, De Zeeuw R A. Development of a radioreceptor assay for the D2-selective dopamine agonist N-0437. Pharm Res 1988; 5: 283–7
   PubMedGoogle Scholar
• Munson P J, Rodbard G J. A versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 1980; 107: 220–39
   PubMed Web of Science ®Google Scholar
• Greenlee W F, Poland A. An improved assay of 7-ethoxycoumarin O-deethylase activity in C57BL/6J and DBA/2J mice by phenobarbital, 3-methylcholanthrene and 2,3,7,8 tetrachlorodibenzodioxin. J Pharm Exp Ther 1978; 205: 596–605
   PubMed Web of Science ®Google Scholar
• Gerding T K, Drenth B FH, De Zeeuw R A. Isotopic separations of the drug N-0437 and its diasteroisomeric glucuronides by HPLC. Anal Chem 1988; 171: 382–8
   Google Scholar
• Kolbe D L, Koons J L, Fischer L F. Metabolism and disposition of the dopaminergic agonist 5-hydroxy-6-methyl-2-di-n-propylaminotetralin in the rat. Drug Metab Dispos 1985; 13: 305–11
   PubMedGoogle Scholar
• Masumoto H, Ohta S, Hirobe M. Application of chemical cytochrome P-450 model system to studies on drug metabolism: IV. Mechanism of piperidine metabolism pathways via an iminium intermediate. Drug Metab Dispos 1991; 19: 768–80
   PubMed Web of Science ®Google Scholar